Company intelligence / Profile preview
Chengdu Peide Biopharmaceutical
Sichuan/Chengdu*, Sichuan Sheng, Chinacrunchbase.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Chengdu Peide Biopharmaceutical has a pipeline focused on synthetic peptides, small molecules, and recombinant polypeptides. Its lead asset for acne vulgaris is in Phase 1 clinical trials. Other programs are at preclinical or discovery stages, targeting neuralgia, pulmonary fibrosis, and vascular diseases. No published clinical results are available as of June 2025.
- Therapeutic areas
- PulmonologyDermatologyCardiovascularNeurology
- Modalities
- Synthetic peptideSmall moleculeRecombinant polypeptide
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Chengdu Peide Biopharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chengdu Peide Biopharmaceutical.